HomeCompareLPCUF vs EPRT

LPCUF vs EPRT: Dividend Comparison 2026

LPCUF yields 3.16% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $43.2K in total portfolio value
10 years
LPCUF
LPCUF
● Live price
3.16%
Share price
$0.19
Annual div
$0.01
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full LPCUF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — LPCUF vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPCUFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPCUF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPCUF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPCUF
Annual income on $10K today (after 15% tax)
$268.66/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,914.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPCUF + EPRT for your $10,000?

LPCUF: 50%EPRT: 50%
100% EPRT50/50100% LPCUF
Portfolio after 10yr
$41.8K
Annual income
$6,420.52/yr
Blended yield
15.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

LPCUF
No analyst data
Altman Z
2.8
Piotroski
8/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPCUF buys
0
EPRT buys
0
No recent congressional trades found for LPCUF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPCUFEPRT
Forward yield3.16%3.92%
Annual dividend / share$0.01$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%29%
Portfolio after 10y$20.2K$63.4K
Annual income after 10y$0.32$12,840.73
Total dividends collected$319.00$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: LPCUF vs EPRT ($10,000, DRIP)

YearLPCUF PortfolioLPCUF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,858$158.04$11,205$505.18$347.00EPRT
2$11,698$80.19$12,672$682.46$974.00EPRT
3$12,558$40.37$14,490$930.48$1.9KEPRT
4$13,457$20.25$16,786$1,282.69$3.3KEPRT
5$14,409$10.14$19,753$1,791.56$5.3KEPRT
6$15,423$5.07$23,677$2,541.64$8.3KEPRT
7$16,505$2.54$29,008$3,672.99$12.5KEPRT
8$17,661$1.27$36,463$5,425.08$18.8KEPRT
9$18,898$0.63$47,238$8,221.57$28.3KEPRT
10$20,221$0.32$63,385$12,840.73$43.2KEPRT

LPCUF vs EPRT: Complete Analysis 2026

LPCUFStock

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

Full LPCUF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this LPCUF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPCUF vs SCHDLPCUF vs JEPILPCUF vs OLPCUF vs KOLPCUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.